Promoter collection, Human COL1A1 promoter
Alternative name | U2774-2 |
---|---|
Clone info. | PCR amplified human COL1A1 promoter sequence was inserted into a firefly luciferase vector. Cloned fragment: 50202872 to 50201613(NC_000017.11); relatively -1233 to +27, where +1 corresponds to 1 nt of NM_000088.3. |
Comment | PCR cloning, forward primer: CAGTGGGAAGTAGCCCCTAA; reverse primer: AGGAGAAACTCCCGTCTGCT. Entire sequence of promoter region has not been confirmed. |
Vector backbone | pGL4.10 [Luc2] (Plasmid) |
Selectable markers | Amp^r |
Gene/insert name | Human collagen, type I, alpha 1 genomic DNA |
Depositor|Developer | DNA Bank, | |
Remarks, protocol and/or map (pdf) | RDB07459.pdf |
---|
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Information of Request for Distribution.[link] |
---|---|
Terms and conditions for distribution | In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation. |
必要書類 | 提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
---|---|
MTAに書く使用条件 | 謝辞の表明を必要とする。 MTAに書く付加的使用条件: 本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。 |
Catalog # | Resource name | Shipping form | Fee (non-profit org.) |
---|---|---|---|
RDB07459 | pGL4-phCOL1A1 | DNA solution |
Materials & Methods section:
The pGL4-phCOL1A1 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07459). |
Reference section:
Further references such as user reports and related articles (go to bottom)
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
Test sheet | RDB07459_A1Htp1-2.pdf |
---|
Nucleotide sequence of a portion of this resource (if available).
Primer: pGL4ins_F (Pr0665) Region: pause site,insert 5' Sequence file: RDB07459_A1Htd.seq |
---|
>07459_07459_B1HbF_pGL4ins_F_D01_04_ABI08.ab1 1 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNTCCC CAGNGCAAGT GCAGGTGCCA 61 GAACATTTCT CTGGCCTAAC TGGCCGGTAC CTGAGCTCGC TAGCCTCGAG GATCAGTGGG 121 AAGTAGCCCC TAAAACAAAG TCAATCATCC TCTGCAGCCC ATCCCACACC CCCAAAGGAA 181 AGTTTCACCC AGACACCCAA AATATCCCAT ACATCCCCAA CACTGAGTCC AGGTACAACT 241 GGAGAAGGGG CTTTATGCAG CTCCCAGAAA GACACCCCTT TAGCTAAGTG CCCTCCCTCC 301 ACCCAGGTTC TCTCTGGTTT GACTGTGCTG GGAAGGAGGG TCTCTAAGCA GCCCCTGGCC 361 ACAGCCATGG CAAACAAAAC TCTTCTCTAA GTCACCAATG ATCACAGGCC TCCCACTAAA 421 AATACTTCCC AACTCTGGGG TGGAAGAGTT TGGGGGATGA ATTTTTANGN NNTTGCAAGC 481 CCCAATCCCC ACCTCTGTGT CCCTAGAATC CCCCACCCCT ACCTTGGCTG CTCCATCACC 541 CAACCACCAA AGCTTTCTTC TGCAGAGGCC ACCTAGTCAT GTTTCTCACC CTGCACCTCA 601 GCCTCCCCAC TCCATCTCTC AATCATGCCT ANGGNTTGGA NGAANGCANT TGATTCTGTT 661 CTGGANCACA GCANAAGAAN TGACATCCTC AAAANTAAAA CTCCCNNNNN TGNACCCCTC 721 CNNNNNANNT CTGANNNNNN ANNNNNNNNN N // |
Primer: pGL4ins_R (Pr0666) Region: Luc 5',insert 3' Sequence file: RDB07459_A1Hte.seq |
>07459_07459_B1HbF_pGL4ins_R_E01_05_ABI08.ab1 1 NNNNNNNNNN NNNNNNGGGT NNNNNNCGCT GGGCCCTTCT TAATGTTTTT GGCATCTTCC 61 ATGGTGGCTT TACCAACAGT ACCGGATTGC CAAGCTTGGC CGCCGAGGCC AGATCTTGAT 121 AGGAGAAACT CCCGTCTGCT CCGACGACTG GCCCGGGCCC CTTTTATACT GTCCTGATGG 181 AGAGCAGGGA GGAACCCTGC CCCTCGGAGA GGGGGAGCCG GCCGCCCGTG CCCCAGCCAA 241 TCAGAGCTGC CTGGCCCGGC CCCCAATTTG GGAGTTGGAA TGGAGAGGGG GAGGAGGAGG 301 GAAGGGNNNN NNNNNN // |
Primer: SV40pA_R (Pr0882) Region: SV40 pA,Luc 3' Sequence file: RDB07459_A1Htf.seq |
>07459_07459_B1HbF_SV40pA_R_F01_06_ABI08.ab1 1 NNNNNNNNCN NNNATTTNNN NAATAAAGCA TTTTTTTNNC TGCATTCTAG TTGTGGTTTG 61 TCCAAACTCA TCAATGTATC TTATCATGTC TGCTCGAAGC GGCCGGCCGC CCCGACTCTA 121 GAATTATTAC ACGGCGATCT TGCCGCCCTT CTTGGCCTTA ATGAGAATCT CGCGGATCTT 181 GCGGGCGTCC AACTTGCCGG TCAGTCCTTT AGGCACCTCG TCCACGAACA CAACACCACC 241 GCGCAGCTTC TTGGCGGTTG TAACCTGGCT GGCCACATAG TCCACGATCT CCTTCTCGGT 301 CATGGTTTTA CCGTGTTCCA GCACGACGAC TGCGGCGGGC AGCTCGCCGG CATCGTCGTC 361 GGGCAGGCCG GCGACCCCGG CGTCGAAGAT GTTGGGGTGT TGCAGCAGGA TGCTCTCCAG 421 TTCGGCTGGG GCTACCTGGT AGCCCTTGTA TTTGATCAGG CTCTTCAGCC GGTCCACGAT 481 GAAGAAGTGC TCGTCCTCGT CCCAGTAGGC GATGTCGCCG CTGTGCAGCC AGCCGTCCTT 541 GTCGATGAGA GCGTTTGTAG CCTCGGGGTT GTTAACGTAG CCGCTCATGA TCATGGGGCC 601 ACGGACGCAC AGCTCGCCGC GCTGGTTCAC ACCCAGTGTC TTACCGGTGT CCNAGTCCAC 661 CACCTTANCC TCNAANANNN GNCANCANCN TNGNCNACTG CGNNAGGNTT GNCGTCCCNT 721 TCNGGGGNGN NNNNANTNNN NNNNGNNNNN TNNNN // |
Please visit Sequencing and PCR primers for primer information.
Original, user report and related articles
Featured content